CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Zeo Scientifix Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Zeo Scientifix Inc
3321 College Avenue, Suite 246
Phone: (305) 370-0482p:305 370-0482 DAVIE, FL  33328  United States Ticker: ZEOXZEOX

Business Summary
Zeo ScientifiX, Inc. is a clinical-stage biopharmaceutical company. The Company is primarily focused on developing innovative biological therapeutics for regenerative medicine and the treatment of degenerative diseases. Its proprietary products, including Zofin, which are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles, and Patient Pure X (PPX), an autologous biologic containing a nanoparticle fraction that is precipitated from a patient’s own peripheral blood (RAAM Products). Its RAAM Products and related services are principally used in the health care industry administered through doctors and clinics. It has developed and begun to distribute additional products that incorporate its proprietary ingredients for products to be used in topical aesthetic applications and is actively exploring further development of additional products to be used in other topical aesthetic applications.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
1/31/202510/31/2024YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Interim Chief Executive Officer, Chief Financial Officer, Director Ian T.Bothwell 62 6/1/2024 11/4/2016
Independent Non-Executive Vice Chairman of the Board ChuckBretz 65 9/23/2022 9/23/2022
Chief Scientific and Technology Officer Peter A.Everts 63 2/7/2025 2/7/2025
4 additional Officers and Directors records available in full report.

Business Names
Business Name
BPSR
ClearMind Ventures, LLC
General Surgical Florida, Inc.
OCEL
OCELD
ZEOX

General Information
Number of Employees: 20 (As of 10/31/2024)
Outstanding Shares: 6,344,817 (As of 3/14/2025)
Shareholders: 199
Stock Exchange: OTC


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, March 28, 2025